Pharma Companies Have Increased MRP By 20-50 Per Cent Over The Past Six Months

Palanpur:  A sudden surge in the prices of life-saving drugs has left consumers reeling, as pharma companies have increased costs by 20-50 per cent over the past six months. Essential medications for hypertension, diabetes, cancer and common gastrointestinal ailments have reached new price highs, while the cost of antibiotics used in surgeries has nearly doubled.

Despite the applicability of the Essential Commodities Price Control Act in the state — which grants district magistrates authority to regulate and take action against price violations — there appears to be no enforcement against the profiteering of pharmaceutical companies.

Social activist Subhash Sharma highlighted shocking discrepancies in drug pricing. For instance, Pantoprazole-40 mg, prescribed for acidity, has an MRP of Rs 130 for a strip of 10 tablets, while its actual cost price is just Rs 20. This exposes profit margins exceeding 90 per cent, with some medications reportedly yielding profits of 1,000 per cent to 1,500 per cent for retailers. “This is only one example,” Sharma said, pointing out that similar price gouging affects hundreds of

In the absence of stringent checks, companies print exorbitant maximum retail prices (MRPs) on generic medicines, forcing poor patients to pay unjustified amounts. Many accuse administrative bodies and vigilance agencies of turning a blind eye, enabling pharmaceutical companies to exploit consumers.

A senior official from the state Drug Control Department admitted that state authorities have limited powers in this matter. “The Government of India has allowed pharma companies to print MRPs on all drugs, and only the Central Drug Controller can intervene,” the official stated.

Related Posts

  • Pharma
  • July 10, 2025
  • 100 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

  • Pharma
  • July 10, 2025
  • 95 views
Novartis wins approval for first malaria drug for newborns and babies

ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr